RAPT Quote, Financials, Valuation and Earnings

Arbutus Biopharma has a net margin of -- compared to RAPT Therapeutics's net margin of -1472.52%. RAPT Therapeutics's return on equity of -- beat Arbutus Biopharma's return on equity of -67.36%.

RAPT Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 268.1%. On the other hand Arbutus Biopharma has an analysts' consensus of $5.07 which suggests that it could grow by 58.44%. Given that RAPT Therapeutics has higher upside potential than Arbutus Biopharma, analysts believe RAPT Therapeutics is more attractive than Arbutus Biopharma.

RAPT Therapeutics has a beta of 0.003, which suggesting that the stock is 99.7% less volatile than S&P 500. In comparison Arbutus Biopharma has a beta of 1.785, suggesting its more volatile than the S&P 500 by 78.497%.

RAPT Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arbutus Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RAPT Therapeutics pays -- of its earnings as a dividend. Arbutus Biopharma pays out -- of its earnings as a dividend.

RAPT Therapeutics quarterly revenues are --, which are smaller than Arbutus Biopharma quarterly revenues of $1.3M. RAPT Therapeutics's net income of -$18.4M is higher than Arbutus Biopharma's net income of -$19.7M. Notably, RAPT Therapeutics's price-to-earnings ratio is -- while Arbutus Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RAPT Therapeutics is 19.41x versus 87.99x for Arbutus Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Assembly Biosciences has a net margin of -- compared to RAPT Therapeutics's net margin of -140.44%. RAPT Therapeutics's return on equity of -- beat Assembly Biosciences's return on equity of -115.86%.

RAPT Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 268.1%. On the other hand Assembly Biosciences has an analysts' consensus of -- which suggests that it could grow by 107%. Given that RAPT Therapeutics has higher upside potential than Assembly Biosciences, analysts believe RAPT Therapeutics is more attractive than Assembly Biosciences.

RAPT Therapeutics has a beta of 0.003, which suggesting that the stock is 99.7% less volatile than S&P 500. In comparison Assembly Biosciences has a beta of 0.564, suggesting its less volatile than the S&P 500 by 43.624%.

RAPT Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assembly Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RAPT Therapeutics pays -- of its earnings as a dividend. Assembly Biosciences pays out -- of its earnings as a dividend.

RAPT Therapeutics quarterly revenues are --, which are smaller than Assembly Biosciences quarterly revenues of $6.8M. RAPT Therapeutics's net income of -$18.4M is lower than Assembly Biosciences's net income of -$9.6M. Notably, RAPT Therapeutics's price-to-earnings ratio is -- while Assembly Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RAPT Therapeutics is 19.41x versus 3.45x for Assembly Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -- compared to RAPT Therapeutics's net margin of 14.23%. RAPT Therapeutics's return on equity of -- beat Biomarin Pharmaceutical's return on equity of 6.29%.

RAPT Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 268.1%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.02 which suggests that it could grow by 47.51%. Given that RAPT Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe RAPT Therapeutics is more attractive than Biomarin Pharmaceutical.

RAPT Therapeutics has a beta of 0.003, which suggesting that the stock is 99.7% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.289, suggesting its less volatile than the S&P 500 by 71.112%.

RAPT Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RAPT Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

RAPT Therapeutics quarterly revenues are --, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. RAPT Therapeutics's net income of -$18.4M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, RAPT Therapeutics's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 39.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RAPT Therapeutics is 19.41x versus 4.74x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

GlycoMimetics has a net margin of -- compared to RAPT Therapeutics's net margin of --. RAPT Therapeutics's return on equity of -- beat GlycoMimetics's return on equity of --.

RAPT Therapeutics has a consensus price target of $4.00, signalling upside risk potential of 268.1%. On the other hand GlycoMimetics has an analysts' consensus of -- which suggests that it could grow by 291.7%. Given that GlycoMimetics has higher upside potential than RAPT Therapeutics, analysts believe GlycoMimetics is more attractive than RAPT Therapeutics.

RAPT Therapeutics has a beta of 0.003, which suggesting that the stock is 99.7% less volatile than S&P 500. In comparison GlycoMimetics has a beta of 1.838, suggesting its more volatile than the S&P 500 by 83.835%.

RAPT Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlycoMimetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RAPT Therapeutics pays -- of its earnings as a dividend. GlycoMimetics pays out -- of its earnings as a dividend.

RAPT Therapeutics quarterly revenues are --, which are smaller than GlycoMimetics quarterly revenues of --. RAPT Therapeutics's net income of -$18.4M is lower than GlycoMimetics's net income of -$9.8M. Notably, RAPT Therapeutics's price-to-earnings ratio is -- while GlycoMimetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RAPT Therapeutics is 19.41x versus -- for GlycoMimetics. Usually stocks with elevated PS ratios are considered overvalued.